Australia markets open in 6 minutes

BioNTech SE (BNTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
98.75+5.52 (+5.92%)
At close: 04:00PM EDT
98.90 +0.15 (+0.15%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close93.23
Open94.00
Bid98.67 x 200
Ask98.78 x 200
Day's range92.39 - 103.40
52-week range85.21 - 125.83
Volume2,728,225
Avg. volume675,524
Market cap23.798B
Beta (5Y monthly)0.25
PE ratio (TTM)193.63
EPS (TTM)0.51
Earnings date05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date02 June 2022
1y target est116.26
  • GlobeNewswire

    BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

    BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African countries and in compliance with global standards Partnership intends to contribute to building a sustainable and resilient end-to-end African vaccine ecosystemBioNTech and CEPI commi

  • PR Newswire

    MediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership

    MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink's TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.

  • GlobeNewswire

    BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024

    MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi